Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Switch to FNB Business

Product shop

By Turnover

First Business Zero (R0 - R5 million p.a) Gold Business (R0 - R5 million p.a) Platinum Business (R5 million - R60 million p.a) Enterprise Business (R60 million - R150 million+ p.a)

Transact

Business Accounts Credit Cards Cash Solutions Merchant Services eWallet Pro Staffing Solutions ATM Solutions Ways to bank Fleet Services Guarantees

Savings and Investments

Save and Invest 3PIM (3rd Party Investment Manager)

Borrow

FNB Cash Advance Overdraft Loans Debtor Finance Leveraged Finance Private Equity Securities Based Lending Selective Invoice Discounting Asset Based Finance Alternative Energy Solutions Commercial Property Finance Fleet Services

Insure

Insurance

For my employees

Staffing Solutions Employee benefits

Forex + Trade

Foreign Exchange Imports and exports Structured Trade + Commodity Finance Business Global Account (CFC account)

Value Adds + Rewards

Connect my business the dti initiatives Enterprise and supplier development Business Hub eBucks Rewards for Business DocTrail™ CIPC Integration Channel Instant Accounting Solutions Instant Payroll Instant Cashflow Instant Invoicing SLOW 24/7 Business Desk FNB Business Fundaba nav» Marketplace Prepaid products Accounting integrations

Industry Expertise

Philanthropy Chinese Business Islamic Banking Agriculture Public Sector Education Healthcare Franchise Motor Dealership Tourism

Going Global

Global Commercial Banking

Financial Planning

Overview

Bank Better

KYC / FICA Debit order + recipient switching Electronic Alerts

Corporates + Public Sector

Corporate Public Sector

All savings + investment accounts


Cash deposits

Notice deposits Immediate access Access to a portion Fixed deposits

Share investing

Shares

Tax-free investing

Tax-free accounts

Funds/unit trusts

Ashburton specialised products

Invest abroad

Offshore products

I want to save for

Personal goals Child's education Emergencies Tax-free

Compare similar

Compare

Additional options

Show me all Help me chosse Find an advisor

Financial planning

Overview

Back

Trade Ideas

Local Trade Idea: Dis-Chem Pharmacies (DCP) - BUY

 

By Peet Serfontein & Jalpa Bhoolia

Dis-Chem is one of the leading pharmaceutical and consumer wellness groups in South Africa. The group takes a 'Pharmacy First' approach with the main aim of serving the primary pharmaceutical needs of individuals. Other products on offer include personal and beauty products, health, nutrition and baby care products, as well as confectionery, dry grocery, household and other ancillary goods. The group utilises its wholesale business to service third parties and Dis-Chem retail pharmacies through its CJ distribution business.

Dis-Chem is also the market leader in dispensary, and we are positive on the growth prospects of this space.

Technically, a share price that reflects higher highs and higher lows makes for a compelling investment opportunity (see the insert on the main chart).

Higher lows indicate increased buying at progressively higher price points, thus preventing the price from falling to a previous low. Higher highs signify that investors are willing to pay more, in turn pushing the price to new peaks. This is supportive of a bullish case for the share.

The share is in a “markup” phase of the Wyckoff market cycle analysis. This phase is characterised by higher highs and higher lows, often accompanied by rising volume, confirming the bullish sentiment around the share.

The share remains above its 200-day and 200-week simple moving averages.

According to the RSI (Relative Strength Index), the stock will be overbought at ~R39, which is the same level at which we have pegged our profit target.

We suggest a medium capital at-risk allocation to this trade.

Share Information

Share Code DCP
Industry Consumer Staples Distribution
Market Capital (ZAR) 30.02 billion
One Year Total Return 51.31%
Return Year-to-Date 14.45%
Current Price (ZAR) 34.90
52 Week High (ZAR) 35.50
52 Week Low (ZAR) 22.30
Financial Year End February
The share has made good progress year-to-date, and technical indicators are supportive of further upside. Expect moderate volatility in the share price.

Consensus expectations

(Bloomberg)

FY23 FY24E FY25E FY26E
Headline Earnings per Share (ZAR) 1.15 1.34 1.61 1.91
Growth (%) 16.75 20.18 18.72
Dividend Per Share (ZAR) 0.46 0.54 0.65 0.81
Growth (%) 18.60 20.48 24.35
Forward PE (times) 26.08 21.70 18.28
Forward Dividend Yield (%) 1.55 1.87 2.33
Attractive double-digit earnings growth is expected over the forecast horizon.

Rationale

Technical Analysis:

  • The lower panel shows the bullish trend period for the share measured in weeks.
  • Note the prolonged upward movement which suggests that buyers consistently outweigh sellers, leading to higher demand and rising prices
  • The recent steep upwards trajectory of the on-balance volume (OBV) indicator supports the bullish undertone
  • Fading downside price momentum according to the MACD (Moving Average Convergence Divergence) histogram is another positive takeaway.
  • The RSI is in oversold territory when the reading is below 30 and overbought when the reading is above 70. The current reading of the RSI is 61, leaving some room to the upside.
  • Our entry range is between R34 and R35. Our upside target is set at R39 (+13% from current levels).
  • Our proposed time to exit is middle-September 2024. Keep the option open to close the trade if the price reaches our profit target in a shorter time.
  • A drop below R33 (~4.4% below current levels) is a concern for downside potential. As such, a stop-loss is recommended at this level.

Long-term fundamental view:

  • We are positive on the health and beauty retail space in the South African context. Within this area, the company is the market leader in Dispensary, Vitamins and Supplements, and Healthcare and Nutrition. Other products on offer include personal and beauty products, health, nutrition, and baby care products, as well as confectionery, dry grocery, household and other ancillary goods.
  • Private label accounts for a big portion of sales, with the possibility of increasing over time - these products tend to carry higher margins.
  • Dis-Chem's franchise model, The Local Choice, is an interesting differentiator for the business and is growing quickly. This business will also drive supply chain volumes, and perhaps margins, in CJ distribution. Through this partner model, it may also provide the larger group with opportunities to absorb once-independent pharmacies.
  • Dis-Chem's results for the year ended 29 February 2024 were decent, with the top- and bottom-line coming in ahead of consensus expectations.
  • Notably, growth improved in the second half as the first half was heavily impacted by diesel expenses, IT-related costs, and advertising expenditure. Additionally, the base for the second half was less demanding. Despite growth in income and profitability, margins shrunk, dragged particularly by retail. Management noted that this was due to higher promotional activity to ensure market share retention. Finance related costs were also meaningfully higher given the high interest rate environment.
  • The post-FY24 period revenue number for the three months is looking strong and is tracking ahead of current market expectations for FY25.
  • Progress on the group's seven strategic growth drivers announced in November 2023 remains on track and benefits are paying off, with momentum expected to pick up over FY25, hopefully to the aide of margins.
  • Risks to our fundamental view include bumpy store-rollouts (revenue growth could be lower compared to current market assumptions). Cannibalisation and persistent competition are also a key risk. Finally, Dis-Chem has always been a closely held, “family run” business and the transition post-Saltzman's exit could be challenging.

Share Name and position VOD - Stop Loss
(Close the Position)
ANH - BUY
(Continue to hold)
OMU - BUY
(Continue to hold)
Entry 97.51 1088.49 11.99
Current 91.19 1105.47 11.98
Movement -6.5% 1.6% -0.1%
The share hit our stop-loss level, leading us to close the position. Additionally, the share crossed below its 200-day simple moving average, signalling a concerning trend. A price that is forming a developing ascending triangle pattern remains of interest. Fading downside price momentum is supportive. Remains just below its 200-day simple moving average.

Our take profit target remains at R1235 with a trailing stop-loss level at R1047. Exit the trade on 28 October 2024.
A price that is building a base remains of interest. Upside price momentum has halted which presents some concern. Remains just above its 200-day simple moving average.

Our profit target is at R14 with a trailing stop-loss at R11.15. Exit the trade on 16 September 2024.

Share Name and position NRP - BUY
(Continue to hold)
EXX - BUY
(Continue to hold)
Entry 131.00 194.83
Current 130.52 191.45
Movement -0.4% -1.7%
An inclining channel pattern remains of interest. Downside price momentum is a concern. Remains above its 200-day simple moving average.

Our take profit target remains at R146 with a trailing stop-loss level at R125. Exit the trade on 9 September 2024.
A price that is forming a developing symmetrical triangle pattern remains of interest. Remains above its 200-day simple moving average.

Our profit target is at R215 with a trailing stop-loss at R183. Exit the trade on 4 November 2024.

FNB Stockbroking and Portfolio Management (Pty) Ltd, a subsidiary of FirstRand Bank Limited, an authorised Financial Services Provider and authorised user of the JSE limited (Reg no: 1996/011732/07). This Publication note is issued by FNB Stockbroking and Portfolio Management (Pty) Ltd for the information of clients only and should not be produced in whole or part without prior permission. Although FNB Stockbroking and Portfolio Management (Pty) Ltd is an Authorised Financial Services Provider, any opinions and/or analysis contained in this Publication are for informational purposes only and should not be considered advice, including but not limited to financial, legal or tax advice, or a recommendation to invest in any security or to adopt any investment strategy. The information contained herein has been obtained from sources/persons which we believe to be reliable but is not guaranteed for correctness, completeness or otherwise and we do not assume liability for loss arising from errors in the information or that may be suffered from using or relying on the information contained herein irrespective of whether there has been any negligence by us, our affiliates or any other employees of us, and whether such losses be direct or consequential. As market and economic conditions are subject to rapid change, any comments, opinions, and analysis is rendered as of the date of publishing and may change without notice. Such changes may have a material impact on the outcome of any investment. Securities involve a degree of risk and are volatile instruments. Past performance is not indicative of future performances. Securities or financial instruments mentioned in the Publication note may not be suitable for all investors and FNB Stockbroking and Portfolio Management (Pty) Ltd has bares no responsibility whatsoever arising from or as a consequence hereof. The material is not intended as a complete analysis of every material fact regarding any share, instrument, sector, region, market, country, investment, or strategy. The recipient of this Publication must make their own investment decision and is advised to contact his relationship manager for a personal financial analysis prior to making any investment decisions. Copyright 2018 by FNB Stockbroking and Portfolio Management (Pty) Ltd.

How would you like to log in?